(CercleFinance.com) – Neovacs jumped 17% after the signing by the biotechnology company with Biosense Global of a new partnership agreement to allow a technology transfer of the product IFN to Kinoid in the treatment of lupus.
“This agreement allows the resumption of clinical trials in China, fully supported by Biosense Global, and offers Neovacs a new perspective for the valuation of a strategic asset without any incurred cost,” she explains.
Neovacs retains all the exploitation rights to the product, excluding China, where Biosense Global benefits from geographic exclusivity and will pay milestones and royalties in the event of commercialization.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
